Today, generic medicines play an essential role in treating disease by increasing the accessibility and affordability of modern day pharmaceuticals. It is therefore essential to ensure that generics can enter the market as soon as possible after patent and data exclusivity protections expire and compete effectively in order to maintain a sustainable generics industry.
A sustainable generics industry in the EU
Home/Reports | Posted 19/08/2011 0 Post your comment
The three pillars for obtaining such a sustainable generics industry are as follows:
Fair access to market
- No hurdles to entry after patent/data exclusivity expiry
- Efficient EU regulatory framework
Fair pricing
- Profitability
- Affordability
- Savings
Fair competition
- Stimulate market competition
- Ban anti-competitive behaviours
The long-term sustainability of the generic medicines sector relies on fair prices and a level playing field. Acceptable margins across the entire generic medicines supply chain will be essential if their full value is to be realised. It is important to increase patient access to generic medicines and there are many benefits to be gained from their faster uptake. Treating them solely as a cost-saving mechanism will serve only to stifle their ability to deliver continued benefits long-term.
Generic medicines provide an opportunity to obtain similar treatments at lower costs for patients and payers, while liberating budgets for financing new innovative medicines. However, in order to achieve these benefits there needs to be a level playing field and governmental policies which maintain a sustainable generics industry.
Related articles
Generic drugs – registration, quality, value and sustainability
The role of generic drugs in the EU
Registration procedures for generic drugs in the EU
Quality control for generic drugs
Generic applications in the EU, patents and exclusivity
Source: EGA, IMS Health
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Comments (0)
Post your comment